Therapeutic Advances in Musculoskeletal Disease (Mar 2019)

Serum chitotriosidase and neopterin levels in patients with ankylosing spondylitis

  • Ferdi Yavuz,
  • Bilge Kesikburun,
  • Özlem Öztürk,
  • Ümüt Güzelküçük

DOI
https://doi.org/10.1177/1759720X19832321
Journal volume & issue
Vol. 11

Abstract

Read online

Background: The aim of this study was to assess the serum chitotriosidase (ChT) and neopterin levels in patients with ankylosing spondylitis (AS) and to evaluate whether serum ChT and neopterin levels are related to disease activity. Methods: A total of 86 patients with AS were included in the study. Patients were divided into two groups based on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores: The active AS patients group included 40 patients who had a BASDAI score ⩾4. The inactive AS patients group included 46 patients who had a BASDAI score 0.05). Higher disease activity (BASDAI score ⩾4) was found to be associated with ChT ( p = 0.012) in the multiple logistic regression analysis. Conclusion: The present study emphasized that serum ChT levels can be useful in the determination of the disease activity of AS patients.